Literature DB >> 28516187

[The aged scalp : A dermato-oncological focus point].

N Wroblewski1, K Wylon2, C Ulrich2.   

Abstract

Non-melanoma skin cancer and its precursor lesions are common diagnoses in dermatological practice, due to rising incidence and prevalence. Diagnosis is often clinical with subsequent histological confirmation. First-choice treatment for invasive carcinomas is complete surgical excision. Other therapeutic options, such as radiation or systemic therapies, should only be considered when excision is impossible. Mostly located on parts of the scalp that are poorly visible and accessible, particularly for elderly patients, these lesions are a challenge for physicians and patients alike. Especially regarding precursor lesions, the therapeutic options are numerous and should be adapted to the individual patient. The main risk factor for development of non-melanoma skin cancer and its precursor lesions is chronic UV exposure. A possible occupational context should always be considered. Preventative methods based on patient education and adequate sun protection behavior are particularly important. The prognosis of non-melanoma skin cancer improves significantly with early diagnosis, as well as with guideline-compatible treatment and follow-up.

Entities:  

Keywords:  Actinic keratosis; Basal cell carcinoma; Precancerous conditions; Squamous cell carcinoma; UV light

Mesh:

Substances:

Year:  2017        PMID: 28516187     DOI: 10.1007/s00105-017-3988-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  80 in total

Review 1.  Demographics and psychological implications for the aging population.

Authors:  A M Kligman; C Koblenzer
Journal:  Dermatol Clin       Date:  1997-10       Impact factor: 3.478

2.  A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.

Authors:  Andrew C Chen; Andrew J Martin; Bonita Choy; Pablo Fernández-Peñas; Robyn A Dalziell; Catriona A McKenzie; Richard A Scolyer; Haryana M Dhillon; Janette L Vardy; Anne Kricker; Gayathri St George; Niranthari Chinniah; Gary M Halliday; Diona L Damian
Journal:  N Engl J Med       Date:  2015-10-22       Impact factor: 91.245

3.  Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.

Authors:  Neil Korman; Ron Moy; Mark Ling; Robert Matheson; Stacy Smith; Scott McKane; James H Lee
Journal:  Arch Dermatol       Date:  2005-04

4.  A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ.

Authors:  Meri Övermark; Sari Koskenmies; Sari Pitkänen
Journal:  Acta Derm Venereol       Date:  2016-01       Impact factor: 4.437

5.  Prevalence of solar damage and actinic keratosis in a Merseyside population.

Authors:  A A Memon; J A Tomenson; J Bothwell; P S Friedmann
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

6.  Risk factors for early-onset basal cell carcinoma in a German institution.

Authors:  Renato Marchiori Bakos; Martin Kriz; Michael Mühlstädt; Christian Kunte; Thomas Ruzicka; Carola Berking
Journal:  Eur J Dermatol       Date:  2011 Sep-Oct       Impact factor: 3.328

Review 7.  [Actinic keratoses].

Authors:  T Hommel; R-M Szeimies
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

Review 8.  [Cutaneous squamous cell carcinoma].

Authors:  U Leiter; R Gutzmer; M Alter; C Ulrich; A S Lonsdorf; M M Sachse; U Hillen
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

Review 9.  Cryosurgery for common skin conditions.

Authors:  Mark D Andrews
Journal:  Am Fam Physician       Date:  2004-05-15       Impact factor: 3.292

10.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.